We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Metabolism-Based Blood Test to Detect Multiple Cancer Types Prior to Symptoms

By LabMedica International staff writers
Posted on 22 Jun 2022
Print article
Image: The first metabolism-based multi-cancer early detection test is expected to become commercially available (Photo courtesy of Pexels)
Image: The first metabolism-based multi-cancer early detection test is expected to become commercially available (Photo courtesy of Pexels)

A pioneering metabolism-based liquid biopsy could detect any-type cancer in adults who show no symptoms or have any recent history of cancer, thereby preventing cancer mortality through early detection.

Elypta (Stockholm, Sweden), which aims to commercialize the first metabolism-based liquid biopsy for early detection of any cancer, will develop and validate blood and urine tests for Multi-Cancer Early Detection (MCED) in adults with no symptoms of cancer and for detection of recurrence in kidney cancer patients. The tests are based on the exhaustive profiling of human glycosaminoglycans - also known as the GAGome - as biomarkers of cancer metabolism, an approach pioneered by Elypta.

Metabolic reprogramming is a hallmark of cancer. Cancer cells need to rewire the way they procure energy and nutrients to support abnormal proliferation and growth. Yet, metabolism is an under-investigated layer of information to identify biomarkers for cancer. By overlaying genome-wide omics data onto the largest reconstruction of the human metabolic network, Elypta identified the profile of the GAGome as the most deregulated panel of metabolites in cancer.

Recent evidence suggests that metabolic reprogramming of GAGomes is a ubiquitous process in cancers. In a clinical study with over 1500 samples across 14 cancer types, a multi-cancer GAGome signature was detected in the plasma and urine that was significantly elevated already in stage I in every cancer type tested. Preclinical evidence in mice supports a causal link between cancer initiation and changes in the GAGome providing mechanistic insight on its value for early detection.

“Our MCED test has the potential to greatly increase the share of cancers detected at the earliest stages when treatment could mean a cure besides being less costly,” said Francesco Gatto, CSO & Founder of Elypta. “Detecting stage I cancer is the key challenge here, and whereas other MCED tests based on cell free DNA struggle to find cancer at this early stage, metabolism-based biomarkers could really make a difference.”

Related Links:
Elypta 

Gold Supplier
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
New
Cytomegalovirus ELISA Test
Captia Cytomegalovirus (CMV) IgM EIA
New
POC Pathogen Detection & Gene Expression System
Sal6830 Mobile Workstation
New
Silver Supplier
SARS-CoV-2, Influenza A/B Test
REALQUALITY ABFlu-Cov-2

Print article
IIR Middle East

Channels

Technology

view channel
Image: OneDraw Blood Collection Device significantly reduces obstacles for drawing blood (Photo courtesy of Drawbridge Health)

Near Pain-Free Blood Collection Technology Enables High-Quality Testing

Blood tests help doctors diagnose diseases and conditions such as cancer, diabetes, anemia, and coronary heart disease, as well as evaluate organ functionality. They can also be used to identify disease... Read more

Industry

view channel
Image: The global infectious disease IVD market is expected to hit USD 57 billion by 2030 (Photo courtesy of Pexels)

Global Infectious Disease IVD Market Dominated by Molecular Diagnostics Technology

The global infectious disease in vitro diagnostics (IVD) market stood at USD 113.7 billion in 2021 and is expected to grow at a CAGR of -7.41% from 2022 to 2030 to hit around USD 56.89 billion by 2030,... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.